Masterflex SE (ISIN: DE0005492938) announced preliminary results for the 2025 financial year, showing record earnings and confirming its forecast. Group revenue rose to EUR 102.6 million, a 4.6% increase from EUR 98.1 million in the previous year. Operating EBITDA grew by 7.4% to EUR 19.5 million, and operating EBIT increased by 9.8% to EUR 14.0 million, both new records. EBIT reached EUR 13.7 million, up 9.2% from EUR 12.5 million, within the forecast range of EUR 12 million to EUR 15 million.
The company noted that the US subgroup performed particularly well, and demand in medical technology grew dynamically, raising its share of consolidated revenue from 18% in 2024 to 21% in 2025. Despite economic headwinds, especially in Germany, demand in industrial customer sectors and trading declined only moderately. The order backlog remained stable at EUR 19.8 million, consistent with the previous year.
Masterflex also strengthened its financial position. The equity ratio improved to 73.3% from 67.7%, and financial liabilities were significantly reduced. Net debt fell to EUR 2.7 million from EUR 9.0 million, resulting in a debt ratio (net debt/EBITDA) of 0.1, down from 0.5. The company attributed the record results to continuous efficiency improvements and a strong performance in medical technology.
CEO Dr. Andreas Bastin commented, "Despite a continuing challenging economic environment, we met our forecasts in the 2025 financial year, achieved solid revenue growth and slightly increased our profitability thanks to continuous efficiency improvements. The development of our medical technology business and the further strengthening of our balance sheet are particularly pleasing." He added that the company is well positioned to continue its growth course.
The figures are subject to confirmation by auditors and approval by the Supervisory Board. The 2025 consolidated financial statements and the 2026 forecast will be published on March 31, 2026.
For more information, visit the original release at NewMediaWire.
